Earlier, the open offer was challenged in the Israeli Supreme Court, which prohibited the Mumbai-based company from closing the offer until a ruling was delivered in other cases related to the takeover
Indian pharmaceutical major Sun Pharmaceutical today said that a US court has dismissed a litigation filed by Israeli drug firm Taro to block an open offer launched by the domestic pharma major to acquire shares of the Tel Aviv-based company, reports PTI.
"The US district court for the Southern District of New York had dismissed in its entirety the complaint filed by Taro Pharmaceutical Industries Ltd, seeking to block the tender offer by Sun's subsidiary Alkaloida Chemical Company Exclusive Group Ltd to purchase all outstanding ordinary shares of Taro," Sun Pharmaceutical said in a statement.
Sun Pharma is the single-largest shareholder in Taro with over 35% stake. It has been trying to wrest control over Taro ever since its $454-million merger deal in 2007 was unilaterally terminated by the Israeli firm a year later, citing undervaluation.
After this, both the companies filed cases against each other and the matter lay pending in the Israeli Supreme Court.
Alkaloida Chemical had launched an open offer in 2008 for acquiring additional shares of Taro. After this, Taro had filed litigation against the Indian firm in a US district court to block its open offer.
"The court also dismissed Taro's other claims, including breach of contract and misappropriation of trade secrets, for lack of subject matter jurisdiction," the statement said.
The Indian firm claimed that the court has given two weeks' time to Taro for filing an amended complaint in an attempt to fix the defects in its earlier petition.
"However, even if Taro revives its state law claims, it will not entitle Taro to obtain the injunction it was seeking to enjoin consummation of Alkaloida's offer," Sun Pharma claimed.
Earlier, the open offer was challenged in the Israeli Supreme Court, which prohibited the Mumbai-based company from closing the offer until a ruling was delivered in other cases related to the takeover.
Sun said Alkaloida's offer remains subject to a continuing order issued by the Supreme Court of Israel, temporarily prohibiting the closing of the offer until the court issues a decision on the appeal of a separate litigation commenced against Alkaloida and its affiliates by Taro.
Commenting on the development, Sun Pharma chairman and managing director Dilip Shanghvi said, "Sun is pleased, but not surprised, by this decision."
Inside story of the National Stock Exchange’s amazing success, leading to hubris, regulatory capture and algo scam
Fiercely independent and pro-consumer information on personal finance.
1-year online access to the magazine articles published during the subscription period.
Access is given for all articles published during the week (starting Monday) your subscription starts. For example, if you subscribe on Wednesday, you will have access to articles uploaded from Monday of that week.
This means access to other articles (outside the subscription period) are not included.
Articles outside the subscription period can be bought separately for a small price per article.
Fiercely independent and pro-consumer information on personal finance.
30-day online access to the magazine articles published during the subscription period.
Access is given for all articles published during the week (starting Monday) your subscription starts. For example, if you subscribe on Wednesday, you will have access to articles uploaded from Monday of that week.
This means access to other articles (outside the subscription period) are not included.
Articles outside the subscription period can be bought separately for a small price per article.
Fiercely independent and pro-consumer information on personal finance.
Complete access to Moneylife archives since inception ( till the date of your subscription )
